Aselizumab

Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2].

Product Specifications

CAS Number

[395639-53-9]

Product Name Alternative

HuDreg-55

UNSPSC

12352203

Target

P-selectin

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/aselizumab.html

Purity

99.76

Solubility

10 mM in DMSO

Smiles

[Aselizumab]

Molecular Weight

(144.74 kDa)

References & Citations

[1]Seekamp A, et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial. Crit Care Med. 2004 Oct;32 (10) :2021-8. |[2]Rahman I, et al. L-selectin regulates human neutrophil transendothelial migration. J Cell Sci. 2021 Feb 8;134 (3) :jcs250340. |[3]Co MS, et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology. 1999 Mar;4 (3-4) :253-66.